MEP31308A - Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin - Google Patents

Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Info

Publication number
MEP31308A
MEP31308A MEP-313/08A MEP31308A MEP31308A ME P31308 A MEP31308 A ME P31308A ME P31308 A MEP31308 A ME P31308A ME P31308 A MEP31308 A ME P31308A
Authority
ME
Montenegro
Prior art keywords
liquid preparations
group
camptothecin
lyophilized
formula
Prior art date
Application number
MEP-313/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Takahiro Ito
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of MEP31308A publication Critical patent/MEP31308A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-313/08A 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin MEP31308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
MEP31308A true MEP31308A (en) 2010-10-10

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-313/08A MEP31308A (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Country Status (21)

Country Link
US (1) US20050215485A1 (xx)
EP (1) EP1501549A2 (xx)
JP (1) JP3927954B2 (xx)
KR (1) KR100700963B1 (xx)
CN (1) CN100544769C (xx)
AR (1) AR039272A1 (xx)
AU (1) AU2003223120B2 (xx)
BR (1) BR0309283A (xx)
CA (1) CA2480425A1 (xx)
HR (1) HRP20040894A2 (xx)
ME (1) MEP31308A (xx)
MX (1) MXPA04010178A (xx)
MY (1) MY136696A (xx)
NO (1) NO20044964L (xx)
PL (1) PL371677A1 (xx)
RS (1) RS91204A (xx)
RU (1) RU2315623C2 (xx)
TW (1) TW200306314A (xx)
UA (1) UA77295C2 (xx)
WO (1) WO2003086471A2 (xx)
ZA (1) ZA200408008B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714653B1 (en) * 2004-02-13 2010-11-24 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing a camptothecin
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
JP5190958B2 (ja) 2005-07-14 2013-04-24 ウェルスタット バイオロジクス コーポレイション ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
MY158231A (en) 2009-06-22 2016-09-15 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8568735B2 (en) 2009-06-22 2013-10-29 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
WO2016103867A1 (ja) 2014-12-26 2016-06-30 日本化薬株式会社 カンプトテシン類高分子誘導体の医薬製剤
KR20180039628A (ko) * 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
JP6877049B2 (ja) 2015-09-25 2021-05-26 ゼットワイ セラピューティクス インク.Zy Therapeutics Inc. 多糖類−ビタミン共役体を含む粒状物に基づく薬物製剤
AU2017226131A1 (en) 2016-03-01 2018-10-04 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation containing camptothecin-based polymeric derivative
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
WO2023095887A1 (ja) * 2021-11-26 2023-06-01 アステラス製薬株式会社 インドシアニン化合物含有固形医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
MXPA03000387A (es) * 2000-07-13 2003-09-22 Daiichi Seiyaku Co Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
RS91204A (xx) 2006-12-15
MXPA04010178A (es) 2005-06-08
AU2003223120B2 (en) 2006-10-05
KR20050000516A (ko) 2005-01-05
RU2315623C2 (ru) 2008-01-27
WO2003086471A2 (en) 2003-10-23
JP2005523329A (ja) 2005-08-04
PL371677A1 (en) 2005-06-27
NO20044964L (no) 2004-11-15
ZA200408008B (en) 2005-06-13
JP3927954B2 (ja) 2007-06-13
AU2003223120A1 (en) 2003-10-27
TW200306314A (en) 2003-11-16
MY136696A (en) 2008-11-28
KR100700963B1 (ko) 2007-03-28
CA2480425A1 (en) 2003-10-23
CN1646172A (zh) 2005-07-27
US20050215485A1 (en) 2005-09-29
EP1501549A2 (en) 2005-02-02
RU2004133349A (ru) 2005-05-27
HRP20040894A2 (en) 2005-10-31
WO2003086471A3 (en) 2004-04-15
AU2003223120A2 (en) 2003-10-27
UA77295C2 (en) 2006-11-15
BR0309283A (pt) 2005-02-15
CN100544769C (zh) 2009-09-30
AR039272A1 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
MEP31308A (en) Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin
DE69601841D1 (de) Camptothecinderivate
ID25979A (id) TURUNAN-TURUNAN KOMTOTESIN (Pecahan dari P-963785)
ATE422356T1 (de) Pharmazeutische zubereitungen
MEP30008A (en) Sustained release preparations
MEP90708A (en) New pharmaceutical composition
ATE265419T1 (de) Spiro(2.4)heptanaminocarbonsäure und ihre derivate
DE69912313D1 (de) Colchinolderivate als gefässschädigende mittel
BR0211284A (pt) Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
TR200103476T2 (tr) A-beta peptid bileşimleri ve bunları hazırlama yöntemleri
FR2743562B1 (fr) Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
BR0010520A (pt) Novos compostos farmaceuticamente ativos
HRP20050787A2 (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino) phenylacetic acid
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
EA200501129A1 (ru) Парентеральные композиции пептида для лечения системной красной волчанки
DE60217903D1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
WO2007147372B1 (en) Pharmaceutical composition for administration by injection
BR0304925A (pt) Compostos, composições farmacêuticas, e, uso dos compostos
DE69701381T2 (de) Peptid-aldehydderivate als antikoagulierende mittel
TW200509941A (en) Pharmaceutical solution composition